Latest Asx News

Elixinol Wellness reported steady Q3 revenue with a notable 300bps gross margin improvement, driven by e-commerce and core brands, while executing cost reduction initiatives supported by a $2.5 million capital raise.

Terrain Minerals has raised $1.17 million through a placement to fund further drilling at its promising Smokebush Project, targeting high-grade gold and silver deposits.

ASF Group Limited reported a solid cash position of $2.44 million as of September 2025, driven by strategic investment moves and technology development, while extending its share buyback program.

Larvotto Resources has greenlit the Hillgrove Antimony-Gold Project development, securing $175 million in funding and reporting strong high-grade drilling results that bolster its resource base.

Tasman Resources has progressed its exploration efforts at Lake Torrens and Parkinson Dam projects, backed by a recent $850,000 capital raise and strategic board changes.

Anagenics Limited reports a notable improvement in operating cash outflows for 1Q26, driven by cost efficiencies and strong brand performance, with Bouf Haircare on track to exceed $9 million in sales.

Great Divide Mining has poured its first gold at the Challenger Gold Mine, marking a key milestone as it moves from exploration to production. The company raised $1.335 million to support its ramp-up plans amid ongoing joint venture challenges.

Aspire Mining Limited reports significant progress on its Ovoot Coking Coal Project, securing exclusive marketing rights and aligning infrastructure development with government-backed transport projects.

Austral Gold’s Q3 report reveals a sharp production drop at Guanaco following a fatal accident, prompting a downward revision of 2025 output and cost hikes, while Casposo’s refurbishment signals a new growth phase.

Argenica Therapeutics reports ARG-007 is safe in acute ischemic stroke patients and shows promising efficacy signals in a high-risk subgroup, paving the way for a focused Phase 2b trial.

Invion Limited has secured a pivotal FDA Orphan Drug Designation for its lead cancer drug INV043, bolstered its balance sheet with nearly $1.8 million in new funding, and progressed clinical trials targeting skin and anogenital cancers.

Novatti Group has achieved positive operating cashflow and EBITDA for the September quarter, driven by strategic revenue reforms and new commercial contracts with major clients.